<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-6-5217001101-BGD-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">ICDDR,B exit 2017-2019</narrative>
   <narrative xml:lang="SV">ICDDR,B exit 2017-2019</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Center for Diarrhoeal Disease Research, Bangladesh (icddr,b) har inkommit med en ans&#xF6;kan om fortsatt organisationsst&#xF6;d till genomf&#xF6;randet av organisationens strategiska plan 2015-2018. Under perioden december 2017 - december 2019 kommer Sverige att bidra med ett utfasningsst&#xF6;d p&#xE5; SEK 21 400 000 f&#xF6;r att st&#xF6;dja icddr,b i genomf&#xF6;randet av deras strategiska plan. 400 000 SEK kommer att &#xF6;ronm&#xE4;rkas f&#xF6;r en extern utv&#xE4;rdering vid slutet av programmet och 1 000 000 SEK kommer att &#xF6;ronm&#xE4;rkas f&#xF6;r specifik myndighetssamverkan med Patentverket. 

icddr,b &#xE4;r ett internationellt forskningsinstitut inom global h&#xE4;lsa med s&#xE4;te i Bangladesh. Institutet har som m&#xE5;l att hitta l&#xF6;sningar p&#xE5; folkh&#xE4;lsoproblem med ett prim&#xE4;rt fokus p&#xE5; utsatta kvinnor, m&#xE4;n, flickor och pojkar som lever i fattigdom. Sverige har gett st&#xF6;d till icddr,b sedan 1981, b&#xE5;de i form av forskningsst&#xF6;d och av institutionsst&#xF6;d. Ambassaden ing&#xE5;r i en givargrupp som best&#xE5;r av Canada (Global Affairs), United Kingdom (DfID) och Sverige som tillsammans ger &#xE5;terkoppling till icddr,b om deras verksamhet. Uppf&#xF6;ljning och rapportering g&#xF6;rs &#xE5;rligen, och givargruppen turas om att finansiera externa rapporter f&#xF6;r utv&#xE4;rdering och uppf&#xF6;ljning av icddr,b&#xB4;s kontroll och riskhanteringssystem. 

Den f&#xF6;reslagna insatsens m&#xE5;l &#xE4;r att genom institutionellt st&#xF6;d skapa m&#xF6;jligheter f&#xF6;r icddr,b att implementera den strategiska planen. Planen f&#xF6;r 2015-2018 har fokus p&#xE5; f&#xF6;ljande 6 strategiska m&#xE5;l:

-	Implementering av forskningsstrategin inom folkh&#xE4;lsa
-	&#xD6;ka synligheten och effekten av forskningsbevis
-	Investering i icddr,b&#xB4;s forskningsplattformar
-	Investering i kunskap och kompetens
-	F&#xF6;rb&#xE4;ttra organisationens effektivitet and kostnads-effektivitet
-	S&#xE4;kerst&#xE4;lla finansiell h&#xE5;llbarhet

Den totala budgeten f&#xF6;r icddr,b f&#xF6;r 2017 &#x2013; 2019 &#xE4;r ca 520 000 000 SEK.

Ambassaden avser att st&#xF6;dja implementeringen av den strategiska planen med ett belopp p&#xE5; 20 400 000 SEK.Ambassadens bed&#xF6;mning &#xE4;r att insatsen &#xE4;r relevant i relation till Sveriges resultatstrategi f&#xF6;r utvecklingssamarbetet med Bangladesh 2014 - 2020, delresultat 4 om grundl&#xE4;ggande h&#xE4;lsa.

English Summary:
During the exit phase Sweden will provide SEK 21 400 000 over the period 2017 - 2019 to support icddr,b in the implementation of the Strategic Plan 2015 - 2018. Sweden has been providing research and core support to icddr,b since 1981 with the aim to ensure that research in health addressed key policy issues for health system in Bangladesh, and that the research findings were communicated to policy users and influenced policy decisions. This objective remains at the core of the Swedish funding during the suggested agreement phase. Core support is suggested as the continued financing modality and it is also suggested to phase out the core support during the 2-year agreement period 2017-2019. Research funding from Sida HQ will continue through an specific agreement for the period 2016-2020 on the amount of MSEK 30,5.

icddr,b has demonstrated the ability to control its own development and preparedness to invest core funds particularly in neglected areas in order to build future capacity. In the coming three years, ambitious efforts are planned to strengthen the capacity of icddr,b with improved monitoring, evaluation and reporting structures and processes as key targets. Achievements in the strategic objectives will be assessed against icddr,b&#xB4;s framework for results that will track output and outcome indicators to monitor progress. Fiduciary risks have been assessed as high but the internal systems related to financial management have been strengthened during the last years and icddr,b has made rapid progress towards reducing these risks. Through its participation in the Core Donor Group, Sweden together with Canada (Global Affairs) and the United Kingdom (Department for International Development  - DfID) will ensure that the risks in the programme are carefully monitored and managed. An external evaluation will be conducted at the end of the agreement to assess the overall success of the programme. The budget for the evaluation has been allocated and is earmarked in the contribution budget.</narrative>
   <narrative xml:lang="EN">Exit support to icddr,b 2017-2018. During the exit phase Sweden will provide SEK 21 400 000 over the period 2017 - 2019 to support icddr,b in the implementation of the Strategic Plan 2015 - 2018. Sweden has been providing research and core support to icddr,b since 1981 with the aim to ensure that research in health addressed key policy issues for health system in Bangladesh, and that the research findings were communicated to policy users and influenced policy decisions. This objective remains at the core of the Swedish funding during the suggested agreement phase.

Core support is suggested as the continued financing modality and it is also suggested to phase out the core support during the 2-year agreement period 2017-2019. Research funding from Sida HQ will continue through an specific agreement for the period 2016-2020 on the amount of MSEK 30,5. icddr,b has demonstrated the ability to control its own development and preparedness to invest core funds particularly in neglected areas in order to build future capacity. In the coming three years, ambitious efforts are planned to strengthen the capacity of icddr,b with improved monitoring, evaluation and reporting structures and processes as key targets.

Achievements in the strategic objectives will be assessed against icddr,b&#xB4;s framework for results that will track output and outcome indicators to monitor progress. Fiduciary risks have been assessed as high but the internal systems related to financial management have been strengthened during the last years and icddr,b has made rapid progress towards reducing these risks. Through its participation in the Core Donor Group, Sweden together with Canada (Global Affairs) and the United Kingdom (Department for International Development - DfID) will ensure that the risks in the programme are carefully monitored and managed. An external evaluation will be conducted at the end of the agreement to assess the overall success of the programme. The budget for the evaluation has been allocated and is earmarked in the contribution budget.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">This support focuses on strengthening the institutional capacity of icddr,b to implement the Strategic Plan 2015 - 2018 that focuses on six goals:
Goal 1: Implement a focused research strategy.  Goal 2: Increase the visibility of and impact of icddr,b&#xB4;s research evidence.  Goal 3: Invest in research platforms.  Goal 4: Invest in people.  Goal 5: Improve organizational efficiency and cost-effectiveness.  Goal 6: Ensure financial sustainability.
Sweden has been providing research and core support to icddr,b since 1981 with the aim to ensure that research in health addressed key policy issues for health system in Bangladesh, and that the research findings were communicated to policy users and influenced policy decisions. This objective remained at the core of the Swedish funding during the phase out agreement phase.</narrative>
  </description>
  <participating-org ref="47053" role="2">
   <narrative xml:lang="EN">ICDDR,B/International Centre for Diarrhoeal Disease Research, Bangladesh</narrative>
  </participating-org>
  <participating-org ref="47053" role="4" type="80">
   <narrative xml:lang="EN">ICDDR,B/International Centre for Diarrhoeal Disease Research, Bangladesh</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-6" role="3" type="10">
   <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2017-08-01" type="1"></activity-date>
  <activity-date iso-date="2017-08-01" type="2"></activity-date>
  <activity-date iso-date="2020-07-31" type="3"></activity-date>
  <activity-date iso-date="2020-07-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
   </organisation>
   <telephone>+46 8 698 50 00</telephone>
   <email>sida@sida.se</email>
   <website>www.sida.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Valhallav&#xE4;gen 199, 105 25 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="BD" percentage="100">
   <narrative xml:lang="EN">Bangladesh</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <tag code="3.D" vocabulary="3">
   <narrative xml:lang="EN">3.d - Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.</narrative>
   <narrative xml:lang="SV">3.d - St&#xE4;rka alla l&#xE4;nders, i synnerhet utvecklingsl&#xE4;ndernas, kapacitet n&#xE4;r det g&#xE4;ller tidig varning, riskreducering och hantering av nationella och globala h&#xE4;lsorisker.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">0</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">1170001.17000117</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">1150695.0197919544</value>
  </budget>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">0</value>
  </budget>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">0</value>
  </budget>
  <planned-disbursement>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">0</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">1170001.1700011694</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">1150695.0197919542</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">0</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">0</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-08-01"></transaction-date>
   <value currency="USD" value-date="2017-08-01">2340002.340002</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-28"></transaction-date>
   <value currency="USD" value-date="2017-12-28">1170001.17000117</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-09-28"></transaction-date>
   <value currency="USD" value-date="2018-09-28">1150695.0197919542</value>
  </transaction>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Results achieved</narrative>
    <narrative xml:lang="SV">Uppn&#xE5;dda resultat</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">The activity period for the phase out core support to icddr,b ended 31 July 2019.
During the 2019 the capacity building support by PRV was implemented as well as the development of a ToR for the evaluation. During 2020 the final evaluation was performed.
Some figures to illustrate icddr,b activities 2019. During the year icddr,b had:- 387 scientific staff and 3 894 non-scientific staff. - 283 551 patients (46 % female) were treated in two hospitals and one treatment centre.- 803 attendees of icddr,b training courses- 119 new grants - 92 national collaborations- 426 original papers published- 394 ongoing projects - 193 international collaborations - 33,121 citations from 2015-2018icddr,b also continues work protecting the health of forcibly displaced Myanmar nationals in Bangladesh.
2020 is the 60th anniversary of the founding of icddr,b, initially known as the Cholera Research Laboratory. The annual report states that the coronavirus pandemic has reinforced the need for constant vigilance against infectious diseases.
The share of total core funding to icddr,b of budget 2019 was 11.3 %, of which the Sida core funding was 13.2 %. The Sida core funding out of icddr,b total budget was 1.5 %.
The Swedish Intellectual Property Office (PRV) had project support 2019-2020 to strengthen the capacity of icddr,b in the area of intellectual property (IP). PRV implemented a project in agreement with the embassy during 2019-2020. The project included awareness raising, needs assessment, workshops, seminars and development of small projects and a policy for IP. PRV&#x2019;s role has been as facilitator. It was of importance that the management of icddr,b owned the process and participated in trainings. The project achieved expected results. For the first time in icddr,b, one application for patent registration and one for copyright registration have been filed, and three patent applications are in the pipeline. Cost for the PRV project were a bit lower, 89 % of budget, due to that no study visit to Sweden was done.
See also Conclusion of Performance 2019-08-18 for more detailed reporting of results.</narrative>
   </description>
   <indicator ascending="0" measure="5">
    <title>
     <narrative xml:lang="EN">Not applicable</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">No indicator available - only a description of the activity results is published</narrative>
    </description>
   </indicator>
  </result>
  <crs-add>
   <other-flags code="2" significance="1"></other-flags>
  </crs-add>
  <sida:contribution contributionid="52170011" xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
  <sida:strategies xmlns:sida="http://sida.se/ns/strategies#">
   <sida:strategy code="1040102" currency="SEK" strategy-amount="1900000000" strategy-end-date="2020-12-31" strategy-start-date="2014-01-01">
    <sida:title>Bangladesh 2014-2020</sida:title>
    <sida:titleSV>Bangladesh 2014-2020</sida:titleSV>
   </sida:strategy>
  </sida:strategies>
 </iati-activity>
</iati-activities>
